While the sample is small (6 patients), it represents an important step in the evidence chain: moving from laboratory proof-of-concept to human clinical testing
In phase II trials focusing on dermal applications, TB-500 has displayed promising outcomes for patients with pressure ulcers, stasis ulcers, and epidermolysis bullosa
Clear procedures reduce contamination risks during medication preparation routines
Unlike classical growth factors, BPC-157 exhibits a high degree of stability in gastric juice and oral bioavailability in animal studies, suggesting potential for systemic therapeutic effects
Absence of documentation should be considered a red flag
Since the majority of clinical trials are either in phase I or II, further evaluation and testing is needed regarding long term toxicity and potential adverse effects associated with those drugs (248252)